Therefore, blocking FKN‐CX3CR1 signaling could serve as a useful therapeutic option not only for rheumatoid arthritis(19) but for osteoporosis by specifically regulating noninflammatory OCPs without directly affecting mature osteoclasts. Here, CX3CR1 is linked to osteoporosis.